KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Debt: 2018-2024

Historic Non-Current Debt for Castle Biosciences (CSTL) over the last 3 years, with Dec 2024 value amounting to $9.7 million.

  • Castle Biosciences' Non-Current Debt rose 0.34% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 0.34%. This contributed to the annual value of $9.7 million for FY2024, which is N/A change from last year.
  • Castle Biosciences' Non-Current Debt amounted to $9.7 million in FY2024, which was down 49.48% from $19.3 million recorded in FY2019.
  • Castle Biosciences' 5-year Non-Current Debt high stood at $9.7 million for FY2024, and its period low was $9.7 million during FY2024.
  • Moreover, its 1-year median value for Non-Current Debt was $9.7 million (2024), whereas its average is $9.7 million.